<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233879</url>
  </required_header>
  <id_info>
    <org_study_id>8591A-020</org_study_id>
    <secondary_id>MK-8591A-020</secondary_id>
    <secondary_id>2019-000590-23</secondary_id>
    <secondary_id>jRCT2031210024</secondary_id>
    <nct_id>NCT04233879</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)</brief_title>
  <official_title>A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a&#xD;
      once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL&#xD;
      [also known as MK-8591A]) in treatment-naïve participants with human immunodeficiency virus&#xD;
      type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity,&#xD;
      safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir&#xD;
      alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior&#xD;
      to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid&#xD;
      (RNA) &lt;50 copies/mL at Week 48.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">February 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies/mL will be determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants discontinuing from study treatment due to AE(s)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 144</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;200 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;200 copies/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;40 copies/mL</measure>
    <time_frame>Week 144</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt;200 copies/mL</measure>
    <time_frame>Week 144</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 48</time_frame>
    <description>CD4+ T-cell counts will be measured by a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 96</time_frame>
    <description>CD4+ T-cell counts will be measured by a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 144</time_frame>
    <description>CD4+ T-cell counts will be measured by a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral resistance-associated substitutions (RASs)</measure>
    <time_frame>Week 48</time_frame>
    <description>The incidence of viral RASs will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral RASs</measure>
    <time_frame>Week 96</time_frame>
    <description>The incidence of viral RASs will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Day 1 (baseline) and Week 48</time_frame>
    <description>The change from baseline in participant body weight will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Day 1 (baseline) and Week 96</time_frame>
    <description>The change from baseline in participant body weight will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Day 1 (baseline) and Week 144</time_frame>
    <description>The change from baseline in participant body weight will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants discontinuing from study treatment due to AE(s)</measure>
    <time_frame>Up to 144 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Group 1: DOR/ISL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants with HIV-1 receive DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) for 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: BIC/FTC/TAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment-naïve participants with HIV-1 receive BIC/FTC/TAF and placebo to DOR/ISL QD for 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR/ISL</intervention_name>
    <description>100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.</description>
    <arm_group_label>Group 1: DOR/ISL</arm_group_label>
    <other_name>MK-8591A</other_name>
    <other_name>Doravirine/islatravir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC/FTC/TAF</intervention_name>
    <description>BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.</description>
    <arm_group_label>Group 2: BIC/FTC/TAF</arm_group_label>
    <other_name>Bictegravir/emtricitabine/tenofovir alafenamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BIC/FTC/TAF</intervention_name>
    <description>Placebo tablet matched to BIC/FTC/TAF taken by mouth.</description>
    <arm_group_label>Group 1: DOR/ISL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to DOR/ISL</intervention_name>
    <description>Placebo tablet matched to DOR/ISL taken by mouth.</description>
    <arm_group_label>Group 2: BIC/FTC/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is HIV-1 positive&#xD;
&#xD;
          -  Is naïve to antiretroviral therapy (ART) defined as having received ≤10 days of prior&#xD;
             therapy with any antiretroviral agent following a diagnosis of HIV-1 infection&#xD;
             including prevention of mother-to-child transmission up to 1 month prior to screening.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies: 1) Is not a woman&#xD;
             of childbearing potential (WOCBP); 2) Is a WOCBP and using an acceptable contraceptive&#xD;
             method, or be abstinent from heterosexual intercourse as their preferred and usual&#xD;
             lifestyle (abstinent on a long term and persistent basis); 3) A WOCBP must have a&#xD;
             negative highly sensitive pregnancy test ([urine or serum] as required by local&#xD;
             regulations) within 24 hours before the first dose of study intervention; 4) If a&#xD;
             urine test cannot be confirmed as negative (eg, an ambiguous result), a serum&#xD;
             pregnancy test is required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has HIV-2 infection&#xD;
&#xD;
          -  Has hypersensitivity or other contraindication to any of the components of the study&#xD;
             interventions as determined by the investigator&#xD;
&#xD;
          -  Has an active diagnosis of hepatitis due to any cause, including active HBV infection&#xD;
             (defined as hepatitis B surface antigen [HBsAg]-positive or hepatitis B virus&#xD;
             deoxyribonucleic acid [HBV DNA]-positive)&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years prior to signing informed consent except for&#xD;
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,&#xD;
             or cutaneous Kaposi's sarcoma&#xD;
&#xD;
          -  Has a history or current evidence of any condition (including active tuberculosis&#xD;
             infection), therapy, laboratory abnormality or other circumstance (including drug or&#xD;
             alcohol use or dependence) that might, in the opinion of the investigator, confound&#xD;
             the results of the study or interfere with the participant's participation for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an&#xD;
             agent that is active against HIV-1&#xD;
&#xD;
          -  Is taking or is anticipated to require systemic immunosuppressive therapy, immune&#xD;
             modulators, or any prohibited therapy from 45 days prior to Day 1 through the study&#xD;
             intervention period&#xD;
&#xD;
          -  Is currently participating in or has participated in a clinical study with an&#xD;
             investigational compound or device from 45 days prior to Day 1 through the study&#xD;
             intervention period&#xD;
&#xD;
          -  Has a documented or known virologic resistance to any approved HIV-1 reverse&#xD;
             transcriptase inhibitor, or any study intervention&#xD;
&#xD;
          -  Has exclusionary laboratory values within 45 days prior to Day 1&#xD;
&#xD;
          -  Is female and is expecting to conceive or donate eggs at any time during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham 1917 Research Clinic ( Site 5610)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-975-4285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pueblo Family Physicians ( Site 5606)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-999-6495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group, Inc. ( Site 5624)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-954-0400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research ( Site 5622)</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Floridian Clinical Research, LLC ( Site 5625)</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-330-9977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group ( Site 5615)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-497-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 5613)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-647-3960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAN Community Health ( Site 5627)</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>941366013411102</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 5621)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-855-7871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute ( Site 5616)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-321-0495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialists Of Atlanta PC ( Site 5608)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare-Hennepin Healthcare-ID ( Site 5633)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>111-111-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City CARE Clinic ( Site 5607)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-777-2757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 5630)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-349-8092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 5629)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-839-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas ID Consultants, PA ( Site 5604)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-276-5618</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Centers for Infectious Disease Associates P.A. ( Site 5619)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>817-348-0042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IDEAA Foundation ( Site 5807)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Caba</state>
        <zip>C1405CKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>541149040623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Huesped ( Site 5801)</name>
      <address>
        <city>C.a.b.a</city>
        <state>Caba</state>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541149817777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Salud S.A. ( Site 5802)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Caba</state>
        <zip>C1141ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>541143637462</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto CAICI ( Site 5803)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414248045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Oulton ( Site 5804)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JJS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>54 3515487840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 5703)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 14K</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9055215075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network ( Site 5705)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4163404800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale L Actuel ( Site 5714)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5145243642271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Research Institute-CVIS Clinical Research Unit ( Site 5702)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5148432090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 5905)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56996420376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Catolica del Maule ( Site 5909)</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3460000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56712635600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 5900)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7560994</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992280653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de la Universidad Catolica ( Site 5903)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8331150</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998211521</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arriaran ( Site 5901)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro Cardiovascular Cardiosur ( Site 5907)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8910259</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56963108092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio ( Site 6005)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110231</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3103322297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 6006)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111321</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5715948650571559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 6001)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573155614943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 6124)</name>
      <address>
        <city>Paris</city>
        <state>Ain</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33140257057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional du Orleans ( Site 6108)</name>
      <address>
        <city>Orleans</city>
        <state>Centre</state>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33238229588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Francois Mitterrand ( Site 6119)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320293305</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux. Hopital Pellegrin ( Site 6116)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795523</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing ( Site 6100)</name>
      <address>
        <city>Tourcoing</city>
        <state>Nord</state>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320694617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix-Rousse ( Site 6127)</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-Alpes</state>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33426732656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 6102)</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33148955146</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris, Hopital Saint Louis ( Site 6114)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine ( Site 6113)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33149283137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere ( Site 6111)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142160142</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Freiburg ( Site 6206)</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wurttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492214783324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München ( Site 6204)</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4989440053550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Munchen am Goetheplatz ( Site 6202)</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49895587030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infektiologikum ( Site 6201)</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 69 69597230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn ( Site 6200)</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4922815421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>EPIMED- Ges. f. epidemiolog. u. klin. Forschung in der Medizin mbH ( Site 6208)</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930265 583 70</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg- Eppendorf (UKE) ( Site 6210)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940741052682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 6701)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247773104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center ( Site 6702)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972507874340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center. ( Site 6704)</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235304937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center ( Site 6700)</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97289441917</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 6705)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. dei Colli - Ospedale Cotugno ( Site 6407)</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390817067406</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 6404)</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39059422466</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII ( Site 6411)</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390352673608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo ASST Monza ( Site 6412)</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0392339310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Amedeo di Savoia ( Site 6414)</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390114393979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 6401)</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390255034763</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salute San Raffaele ( Site 6402)</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390226437934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo ( Site 6403)</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390281843045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli-Ospedale Sacco ( Site 6400)</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390239043490</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo ( Site 6410)</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0382502403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani ( Site 6405)</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390655170367</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center ( Site 6903)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81529511111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital ( Site 6905)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81963442111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 69</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669421331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital ( Site 6904)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81333426111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine ( Site 6901)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81332027181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JOSHA Research ( Site 6605)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27514128160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital - ICU ( Site 6608)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119899905</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Health Consortium. Clinical HIV Research Unit ( Site 6614)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27112768800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ezintsha ( Site 6609)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>011-0844933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wentworth Hospital ( Site 6607)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27312054421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit (Fam-Cru)-Adult Infectious Diseases ( Site 6617)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27219389483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation Clinical Trial Unit ( Site 6613)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27214066958</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre ( Site 6603)</name>
      <address>
        <city>Mbekweni, Paarl</city>
        <state>Western Cape</state>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27218683990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elche ( Site 6308)</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34966616756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ( Site 6301)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934978849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge ( Site 6312)</name>
      <address>
        <city>LHospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D Hebron ( Site 6302)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932746090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial ( Site 6300)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon ( Site 6303)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915868591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz ( Site 6307)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915504800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre ( Site 6305)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917792218</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 6304)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917277558</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria ( Site 6309)</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34951032594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital ( Site 7102)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88673422121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 7101)</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-6-2353535 ext.3596</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 7100)</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8862231234566842</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

